| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
22 |
| Employees |
2 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-18 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Propanc Biopharma Inc is a clinical-stage biopharmaceutical company that develops and commercializes treatment options for patients suffering from pancreatic cancer and various gastrointestinal cancers. The company focuses on developing proprietary formulations of proenzymes, which are inactive forms of enzymes, to activate enzymes that can target and destroy cancer cells. These proenzymes aim to improve the efficacy and safety of existing cancer treatments and have the potential to become a major advancement in cancer therapy. Propanc Biopharma is committed to conducting preclinical and clinical trials to develop its lead product, PRP, with the goal of gaining regulatory approval and bringing it to market.
Company Address: 302 Camberwell, VIC 3124
Company Phone Number: 9882-0780 Stock Exchange / Ticker: PPCH
|
%
2.95%